SciSparc Ltd. (SPRC) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
SciSparc Ltd., a pharmaceutical company specializing in central nervous system disorders, has received FDA approval to advance its proprietary SCI-110 drug into Phase IIb clinical trials for the treatment of Tourette Syndrome in adult patients. The company, which had previously demonstrated promising results in Phase IIa trials, will conduct the new trials across three global centers of excellence. SciSparc’s CEO expressed confidence in the drug’s potential to offer a novel treatment for Tourette’s patients.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.
